HealthEquity (NASDAQ:HQY) Stock Price Down 3.1%

HealthEquity, Inc. (NASDAQ:HQY) shares dropped 3.1% during mid-day trading on Wednesday . The company traded as low as $83.06 and last traded at $83.12. Approximately 128,659 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 603,554 shares. The stock had previously closed at $85.76.

Analyst Upgrades and Downgrades

HQY has been the subject of a number of research analyst reports. Bank of America reaffirmed a “buy” rating and issued a $105.00 price target on shares of HealthEquity in a report on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a report on Tuesday, June 4th. Wells Fargo & Company upped their price target on HealthEquity from $107.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, June 20th. BTIG Research boosted their price objective on HealthEquity from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, March 20th. Finally, Barrington Research boosted their price objective on HealthEquity from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Tuesday, June 4th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, HealthEquity has a consensus rating of “Moderate Buy” and a consensus target price of $101.67.

HealthEquity Price Performance

The company has a debt-to-equity ratio of 0.44, a current ratio of 4.39 and a quick ratio of 4.39. The company has a 50 day moving average price of $81.43 and a 200 day moving average price of $78.56. The firm has a market cap of $7.27 billion, a PE ratio of 90.83, a PEG ratio of 1.41 and a beta of 0.57.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Monday, June 3rd. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.08. HealthEquity had a return on equity of 7.77% and a net margin of 7.71%. The firm had revenue of $287.60 million for the quarter, compared to analyst estimates of $278.78 million. Sell-side analysts expect that HealthEquity, Inc. will post 2.12 EPS for the current fiscal year.

Insider Buying and Selling at HealthEquity

In other HealthEquity news, Vice Chairman Stephen Neeleman sold 2,080 shares of the firm’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $85.01, for a total transaction of $176,820.80. Following the completion of the transaction, the insider now directly owns 90,515 shares in the company, valued at approximately $7,694,680.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other HealthEquity news, Vice Chairman Stephen Neeleman sold 2,080 shares of the firm’s stock in a transaction dated Friday, June 7th. The shares were sold at an average price of $85.01, for a total transaction of $176,820.80. Following the completion of the transaction, the insider now directly owns 90,515 shares in the company, valued at approximately $7,694,680.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jon Kessler sold 32,326 shares of HealthEquity stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $82.83, for a total transaction of $2,677,562.58. Following the sale, the chief executive officer now owns 232,176 shares of the company’s stock, valued at $19,231,138.08. The disclosure for this sale can be found here. In the last three months, insiders sold 34,806 shares of company stock worth $2,888,383. 2.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On HealthEquity

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of HealthEquity by 1.7% during the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock worth $715,783,000 after buying an additional 149,133 shares in the last quarter. Wasatch Advisors LP boosted its position in shares of HealthEquity by 8.3% in the first quarter. Wasatch Advisors LP now owns 7,409,080 shares of the company’s stock worth $604,803,000 after acquiring an additional 569,249 shares during the last quarter. Motley Fool Asset Management LLC boosted its position in shares of HealthEquity by 3,001.0% in the first quarter. Motley Fool Asset Management LLC now owns 3,762,064 shares of the company’s stock worth $307,097,000 after acquiring an additional 3,640,748 shares during the last quarter. Clearbridge Investments LLC boosted its position in shares of HealthEquity by 6.9% in the fourth quarter. Clearbridge Investments LLC now owns 2,357,572 shares of the company’s stock worth $156,307,000 after acquiring an additional 152,897 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its position in shares of HealthEquity by 58.2% in the fourth quarter. Mackenzie Financial Corp now owns 1,807,407 shares of the company’s stock worth $119,831,000 after acquiring an additional 664,979 shares during the last quarter. 99.55% of the stock is currently owned by hedge funds and other institutional investors.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.